Related Experiment Videos
Primary bone lymphoma--treatment and outcome
1Oncology Centre, Queen Elizabeth Medical Centre, Birmingham B15 2TH, UK. daniel.ford@uclh.nhs.uk
Clinical Oncology (Royal College of Radiologists (Great Britain))
|February 20, 2007
Summary
Combined modality treatment for primary bone lymphoma (PBL) offers good local control and survival rates. This study found a 10-year survival of 74% with acceptable toxicity in PBL patients.
Area of Science:
- Oncology
- Hematology
- Orthopedic Oncology
Background:
- Primary bone lymphoma (PBL) is a rare malignancy.
- Optimal treatment strategies for PBL require further investigation.
Purpose of the Study:
- To evaluate the outcomes of combined modality treatment for primary bone lymphoma.
- To assess survival rates, relapse-free survival, and toxicity in PBL patients.
Main Methods:
- Retrospective review of 22 patients with histologically confirmed PBL treated between 1985 and 2003.
- Data collected included demographics, stage, treatment (chemotherapy, radiotherapy, surgery), and outcomes.
- International Prognostic Index (IPI) was used for risk stratification.
Main Results:
- The median age of patients was 50 years; 17 had localized disease, 5 multifocal.
- All patients received chemotherapy, 19 with anthracycline-based regimens. Radiotherapy was administered to 18 patients.
- Overall 10-year survival was 74%. Low-risk IPI patients had 92% survival, intermediate-risk 73%. Relapse-free survival was 85%.
Conclusions:
- Combined modality treatment, including chemotherapy and radiotherapy, achieves good local control and survival in PBL.
- Treatment demonstrated acceptable toxicity with low rates of local relapse and manageable orthopaedic complications.
